Accord’s Marc Comas highlights the company’s presence in Spain with leading oncology products, three biosimilars and investment in specialty pharma. He shares his views on the COVID pandemic, the future of the supply chain, the importance of Spain, Barcelona’s attractiveness for the pharma industry, and explains why Accord will be able to compete on price due to its in-house manufacturing capabilities.
Accord recognises biosimilars as a future growth driver for the company. It is common sense as medicine moves to biologics and biologics move toward gene and cell therapy.
